$BFNH
BIOFORCE NANOSCIENCES HOLDINGS, INC.

2021 Q3 Form 10-Q Financial Statement

#000109181821000138 Filed on October 28, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2020 Q3
Revenue $0.00
YoY Change -100.0%
Cost Of Revenue $0.00
YoY Change -100.0%
Gross Profit $0.00 $0.00
YoY Change -100.0%
Gross Profit Margin
Selling, General & Admin $113.9K $117.9K
YoY Change -3.44% 1363.03%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $113.9K $117.9K
YoY Change -3.44% 1363.03%
Operating Profit -$113.9K -$117.9K
YoY Change -3.44% 1759.94%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$113.9K -$117.9K
YoY Change -3.44% 1762.88%
Income Tax
% Of Pretax Income
Net Earnings -$113.9K -$117.9K
YoY Change -3.44% 1762.88%
Net Earnings / Revenue
Basic Earnings Per Share $0.00
Diluted Earnings Per Share -$3.890K -$7.721K
COMMON SHARES
Basic Shares Outstanding 29.27M shares
Diluted Shares Outstanding 29.27M shares

Balance Sheet

Concept 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $27.31K $39.87K
YoY Change -31.5% -15.04%
Cash & Equivalents $27.31K
Short-Term Investments
Other Short-Term Assets $70.00
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $27.38K $39.87K
YoY Change -31.33% -24.62%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $27.38K $39.87K
Total Long-Term Assets $0.00 $0.00
Total Assets $27.38K $39.87K
YoY Change -31.33% -24.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $440.00 $0.00
YoY Change -100.0%
Accrued Expenses $644.8K $221.2K
YoY Change 191.5%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $768.5K $277.2K
YoY Change 177.24% 6005.95%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $768.5K $277.2K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $768.5K $277.2K
YoY Change 177.24% 6005.95%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$741.2K -$237.3K
YoY Change
Total Liabilities & Shareholders Equity $27.38K $39.87K
YoY Change -31.33% -24.62%

Cashflow Statement

Concept 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$113.9K -$117.9K
YoY Change -3.44% 1762.88%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$8.680K -$8.640K
YoY Change 0.46% 382.68%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 8.680K 8.640K
YoY Change 0.46% 11.48%
NET CHANGE
Cash From Operating Activities -8.680K -8.640K
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 8.680K 8.640K
Net Change In Cash 0.000 0.000
YoY Change -100.0%
FREE CASH FLOW
Cash From Operating Activities -$8.680K -$8.640K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001310488
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29271755 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29271755 shares
CY2021Q3 us-gaap Revenues
Revenues
USD
us-gaap Revenues
Revenues
USD
CY2021Q3 us-gaap Cost Of Revenue
CostOfRevenue
USD
us-gaap Cost Of Revenue
CostOfRevenue
USD
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29271755 shares
CY2020 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
1167 shares
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-627302 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-113860 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-741162 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
47308 USD
bfnh Common Stock Issued To Pay Accounts Payable
CommonStockIssuedToPayAccountsPayable
1339 USD
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
158000000 USD
us-gaap Net Income Loss
NetIncomeLoss
-158285990 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-237343 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-359908 USD
us-gaap Net Income Loss
NetIncomeLoss
-381254 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-741162 USD
CY2020Q2 bfnh Business Acquisition Equity Interests Purchased Number Of Shares
BusinessAcquisitionEquityInterestsPurchasedNumberOfShares
100000 shares
CY2020Q2 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
1000 USD
CY2020 us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
1339 USD
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:12pt; margin-bottom:0pt; "> <span style="font-weight:bold; ">Use of Estimates</span></p> <p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:12pt; margin-bottom:0pt; ">The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. </p>
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29271755 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29271755 shares
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29271755 shares
CY2021Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.79
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000 shares

Files In Submission

Name View Source Status
0001091818-21-000138-index-headers.html Edgar Link pending
0001091818-21-000138-index.html Edgar Link pending
0001091818-21-000138.txt Edgar Link pending
0001091818-21-000138-xbrl.zip Edgar Link pending
bfnh-20210930.xsd Edgar Link pending
bfnh-20210930_cal.xml Edgar Link unprocessable
bfnh-20210930_def.xml Edgar Link unprocessable
bfnh-20210930_lab.xml Edgar Link unprocessable
bfnh-20210930_pre.xml Edgar Link unprocessable
bfnh10q0921.htm Edgar Link pending
bfnh10q0921_htm.xml Edgar Link completed
bfnhlogo2019001.jpg Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending